AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]
Go back to AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]| AbbVie (NYSE: ABBV) | Delayed: 254.76 -6.31 (2.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $261.07 | 52 Week High | $68.12 | |||
| Open | $259.92 | 52 Week Low | $50.71 | |||
| Day High | $260.92 | P/E | 55.26 | |||
| Day Low | $253.60 | EPS | $4.61 | |||
| Volume | 8,580,052 | |||||
